SK282614B6 - Vakcína proti chrípke a spôsob jej prípravy - Google Patents

Vakcína proti chrípke a spôsob jej prípravy Download PDF

Info

Publication number
SK282614B6
SK282614B6 SK445-98A SK44598A SK282614B6 SK 282614 B6 SK282614 B6 SK 282614B6 SK 44598 A SK44598 A SK 44598A SK 282614 B6 SK282614 B6 SK 282614B6
Authority
SK
Slovakia
Prior art keywords
surface antigen
influenza
cell culture
dna
virus
Prior art date
Application number
SK445-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK44598A3 (en
Inventor
M. Van Scharrenburg Gustaaf J.
Rudi Brands
Original Assignee
Duphar International Research B. V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK282614(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duphar International Research B. V. filed Critical Duphar International Research B. V.
Publication of SK44598A3 publication Critical patent/SK44598A3/sk
Publication of SK282614B6 publication Critical patent/SK282614B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SK445-98A 1997-04-09 1998-04-06 Vakcína proti chrípke a spôsob jej prípravy SK282614B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201007 1997-04-09

Publications (2)

Publication Number Publication Date
SK44598A3 SK44598A3 (en) 1998-11-04
SK282614B6 true SK282614B6 (sk) 2002-10-08

Family

ID=8228174

Family Applications (1)

Application Number Title Priority Date Filing Date
SK445-98A SK282614B6 (sk) 1997-04-09 1998-04-06 Vakcína proti chrípke a spôsob jej prípravy

Country Status (31)

Country Link
US (1) US5948410A (cs)
EP (1) EP0870508B1 (cs)
JP (1) JP5258127B2 (cs)
KR (1) KR100593235B1 (cs)
CN (1) CN1138564C (cs)
AR (1) AR011216A1 (cs)
AT (1) ATE197406T1 (cs)
AU (1) AU728939B2 (cs)
BR (1) BR9801015A (cs)
CA (1) CA2234208C (cs)
CZ (1) CZ297492B6 (cs)
DE (2) DE69800383T2 (cs)
DK (1) DK0870508T3 (cs)
DZ (1) DZ2462A1 (cs)
ES (1) ES2129386T3 (cs)
GR (2) GR990300017T1 (cs)
HR (1) HRP980187B1 (cs)
HU (1) HUP9800802A3 (cs)
ID (1) ID20399A (cs)
IL (1) IL123961A (cs)
NO (1) NO323349B1 (cs)
NZ (1) NZ330131A (cs)
PL (1) PL187982B1 (cs)
PT (1) PT870508E (cs)
RU (1) RU2197264C2 (cs)
SI (1) SI0870508T1 (cs)
SK (1) SK282614B6 (cs)
TR (1) TR199800613A1 (cs)
TW (1) TW570803B (cs)
UA (1) UA42089C2 (cs)
ZA (1) ZA982915B (cs)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021151A1 (en) * 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CN100415769C (zh) * 2002-02-07 2008-09-03 中国科学院过程工程研究所 寡聚或多聚亚基蛋白质分离纯化的方法
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
EP1597400B8 (en) * 2003-02-25 2013-10-09 MedImmune, LLC Methods of producing influenza vaccine compositions
JP4558652B2 (ja) * 2003-06-20 2010-10-06 マイクロビクス・バイオシステムズ・インコーポレイテツド ウイルス生産の改善
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
WO2005080556A2 (en) 2004-02-23 2005-09-01 Crucell Holland B.V. Virus purification methods
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
RS52400B (sr) 2004-09-09 2013-02-28 Novartis Vaccines And Diagnostics Gmbh Redukcija potencijalnih jatrogenih rizika povezanih sa vakcinom protiv gripa
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CA2586690A1 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
EP1831353B1 (en) * 2004-12-23 2012-02-29 MedImmune, LLC Non-tumorigenic mdck cell line for propagating viruses
WO2006100109A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
WO2006108707A1 (en) * 2005-04-11 2006-10-19 Crucell Holland B.V. Virus purification using ultrafiltration
PL1951296T5 (pl) * 2005-11-01 2015-06-30 Seqirus Uk Ltd Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DE06808434T1 (de) 2005-11-04 2009-12-17 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen phasen tensid als adjuvans für spalt-grippeimpfstoffe
JP2009514841A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 粒子状アジュバントと免疫増強物質との組合せを含むインフルエンザワクチン
CA2628206A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
EP2377551A3 (en) 2005-11-04 2013-04-24 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
NZ570106A (en) * 2006-01-27 2012-04-27 Novartis Vaccines & Diagnostic Influenza vaccines containing hemagglutinin and matrix proteins
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
HRP20140488T1 (hr) 2006-07-17 2014-07-04 Glaxosmithkline Biologicals S.A. Cjepivo protiv influence
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
ES2694805T7 (es) 2006-09-11 2021-10-21 Seqirus Uk Ltd Fabricación de vacunas contra virus de la gripe sin usar huevos
RU2487935C2 (ru) 2006-09-15 2013-07-20 Медиммун, Ллк. Линии клеток почки собаки майдин-дэрби (mdck), поддерживающие рост вирусов до высоких титров, и способ применения этих клеток в биореакторе
ES2480491T3 (es) 2006-12-06 2014-07-28 Novartis Ag Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
RU2456007C2 (ru) * 2007-03-05 2012-07-20 Ом Фарма Бактериальный экстракт против респираторных расстройств и способ его получения
CA2680600A1 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
US8821885B2 (en) * 2007-08-27 2014-09-02 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
NZ587798A (en) 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
JP5654468B2 (ja) 2008-09-24 2015-01-14 メディミューン，エルエルシー 細胞培養、ウイルスの増殖および精製のための方法
US20110217330A1 (en) * 2008-11-05 2011-09-08 Bruno Rene Andre Novel method
JP2012517416A (ja) 2009-02-10 2012-08-02 ノバルティス アーゲー 増加した量のｈ３抗原を含むインフルエンザワクチン
CN102307590A (zh) 2009-02-10 2012-01-04 诺华有限公司 具有减少量的角鲨烯的流感疫苗
EP2942062A1 (en) 2009-02-10 2015-11-11 Novartis AG Influenza vaccine regimens for pandemic-associated strains
JP2012525370A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー インフルエンザに対して防御するためのアジュバント添加ワクチン
US9072702B2 (en) 2009-05-21 2015-07-07 Novartis Ag Reverse genetics using non-endogenous pol I promoters
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CA2767392C (en) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2459722B1 (en) 2009-07-31 2017-09-06 Seqirus UK Limited Reverse genetics systems
KR20120081587A (ko) 2009-09-10 2012-07-19 노파르티스 아게 기도 질병에 대한 조합 백신
EP2491117B2 (en) 2009-10-20 2017-06-28 Novartis AG Improved reverse genetics methods for virus rescue
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
CN103096921A (zh) 2010-06-01 2013-05-08 诺华有限公司 不用冻干疫苗抗原浓缩
NZ603863A (en) 2010-06-01 2014-09-26 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
AU2011276223C1 (en) 2010-07-06 2016-05-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2663288B1 (en) 2011-01-13 2022-12-21 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
EP2747778B1 (en) 2011-08-26 2017-12-06 Wisconsin Alumni Research Foundation Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2780350B1 (en) 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
ES2628301T3 (es) 2012-03-02 2017-08-02 Seqirus UK Limited Recombinación de virus de gripe
US20150161359A1 (en) 2012-06-04 2015-06-11 Novartis Ag Methods for safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
MX2015006927A (es) 2012-12-03 2016-02-05 Novartis Ag Redistribucion de virus de la influenza.
WO2014141125A2 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
BR112015028314A2 (pt) 2013-05-10 2017-09-19 Steinman Lawrence Prevenção do risco de narcolepsia em vacinas para gripe
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
CA2914604A1 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
EP3022296B1 (en) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
RU2535153C1 (ru) * 2013-09-04 2014-12-10 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства России (ФГУП СПбНИИВС ФМБА России) Способ получения высокоочищенных вирионных концентратов
CA2930634C (en) 2013-11-15 2023-05-09 Novartis Ag Removal of influenza nuclear protein (np) from influenza virus preparations
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP2966093A1 (en) 2014-07-07 2016-01-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
RU2614127C2 (ru) * 2015-06-04 2017-03-22 Общество с ограниченной ответственностью "НТфарма" Способ получения концентрата рекомбинантных псевдоаденовирусных частиц, экспрессирующих ген гемагглютинина вируса гриппа A/California/07/2009(H1N1)
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
US20200392468A1 (en) 2017-03-30 2020-12-17 Merck Sharp & Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
EP3700562A1 (en) 2017-10-25 2020-09-02 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
RU2670001C1 (ru) * 2017-12-25 2018-10-17 Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии растений и микроорганизмов Российской академии наук Способ получения белков клеточной поверхности
AU2019207600B2 (en) 2018-01-09 2025-01-09 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
JP2021533157A (ja) 2018-08-07 2021-12-02 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
WO2020041311A1 (en) 2018-08-20 2020-02-27 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
JP2022527235A (ja) 2019-01-23 2022-06-01 義裕 河岡 インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
EP3965805A4 (en) 2019-05-06 2023-01-25 Synthetic Biologics, Inc. ALKALINE PHOSPHATE BASED ONCOLOGICAL TREATMENTS
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
EP4054630A2 (en) * 2019-11-07 2022-09-14 Seqirus UK Limited Compositions and methods for producing a viral vaccine with reduced particle size
WO2021099419A1 (en) 2019-11-18 2021-05-27 Seqirus UK Limited Method for producing reassortant influenza viruses
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (cs) * 1974-01-14 1977-07-15 Sandoz Ag
SU487541A1 (ru) * 1974-05-22 1976-03-25 Всесоюзный научно-исследовательский институт гриппа Способ получени препаратов вируса гриппа
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US4317811A (en) * 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
DE3237313A1 (de) * 1982-10-08 1984-04-12 Werner Heese Verfahren zur gewinnung und reinigung antigenhaltiger loesungen, insbesondere fuer influenza-viren, aus antigenhaltiger allantoisfluessigkeit
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5006472A (en) * 1988-06-03 1991-04-09 Miles Inc. Enzymatic purification process
DE69012903T2 (de) * 1989-02-07 1995-05-11 Bio-Technology General Corp., Iselin, N.J. Verfahren zur herstellung und reinigung von hepatitis b-impfstoff.
ES2081864T3 (es) * 1989-03-29 1996-03-16 Univ New York State Res Found Metodo para purificar una proteina de la membrana exterior de haemophilus influenzae.
DK0528859T3 (da) * 1990-04-24 1998-09-14 Flustat Pty Ltd Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
DZ1706A1 (fr) * 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
RU2082431C1 (ru) * 1993-05-12 1997-06-27 Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им.Пастера Способ получения инактивированной гриппозной вакцины
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
US5612037A (en) * 1994-07-26 1997-03-18 Connaught Laboratories, Inc. Influenza virus subunit conjugates
DK1213030T3 (da) * 1994-11-10 2009-07-20 Baxter Healthcare Sa Fremgangsmåde til fremstilling af biologiske produkter i protein-fri kultur
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
CA2228128C (fr) * 1995-08-01 2011-03-29 Pasteur Merieux Serums & Vaccins Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
EP0863704A4 (en) * 1995-09-28 2003-09-10 Univ Pittsburgh STIMULATION OF CELLULAR IMMUNE RESPONSES BY TARGETED GENE IMMUNIZATION USING A PARTICULATE AGENT
RU2100033C1 (ru) * 1995-10-05 1997-12-27 Санкт-Петербургский научно-исследовательский институт вакцин и сывороток Способ получения вакцинных штаммов вируса гриппа в для производства инактивированных и живых гриппозных вакцин
RU2080124C1 (ru) * 1995-10-19 1997-05-27 Санкт-Петербургский научно-исследовательский институт вакцин и сывороток Способ получения живой гриппозной вакцины
RU2164148C1 (ru) * 2000-08-09 2001-03-20 Петров Рэм Викторович Вакцина против вируса гриппа и способ ее получения

Also Published As

Publication number Publication date
PL187982B1 (pl) 2004-11-30
EP0870508A1 (en) 1998-10-14
AU6065998A (en) 1998-10-15
NO981557L (no) 1998-10-12
DE69800383T2 (de) 2001-08-16
DK0870508T3 (da) 2000-11-20
SI0870508T1 (en) 2001-02-28
ZA982915B (en) 1999-01-21
IL123961A (en) 2000-07-16
GR990300017T1 (en) 1999-06-30
US5948410A (en) 1999-09-07
CZ105098A3 (cs) 1998-10-14
SK44598A3 (en) 1998-11-04
CA2234208A1 (en) 1998-10-09
NO323349B1 (no) 2007-04-02
HRP980187B1 (en) 2001-04-30
HU9800802D0 (en) 1998-05-28
KR100593235B1 (ko) 2007-12-04
ID20399A (id) 1998-12-10
NZ330131A (en) 1999-10-28
PT870508E (pt) 2001-04-30
ATE197406T1 (de) 2000-11-11
NO981557D0 (no) 1998-04-06
UA42089C2 (uk) 2001-10-15
HRP980187A2 (en) 1999-04-30
DE870508T1 (de) 1999-08-19
CN1196956A (zh) 1998-10-28
TR199800613A1 (xx) 1998-10-21
MX9802766A (es) 1998-12-31
EP0870508B1 (en) 2000-11-08
ES2129386T1 (es) 1999-06-16
HK1010833A1 (en) 1999-07-02
JP5258127B2 (ja) 2013-08-07
JPH1121253A (ja) 1999-01-26
CA2234208C (en) 2003-06-10
AR011216A1 (es) 2000-08-02
ES2129386T3 (es) 2001-01-01
RU2197264C2 (ru) 2003-01-27
HUP9800802A3 (en) 2003-08-28
BR9801015A (pt) 2000-01-11
HUP9800802A2 (hu) 1999-04-28
CN1138564C (zh) 2004-02-18
AU728939B2 (en) 2001-01-18
CZ297492B6 (cs) 2007-01-03
DZ2462A1 (fr) 2003-01-18
KR19980081114A (ko) 1998-11-25
GR3034798T3 (en) 2001-02-28
PL325722A1 (en) 1998-10-12
DE69800383D1 (de) 2000-12-14
TW570803B (en) 2004-01-11

Similar Documents

Publication Publication Date Title
SK282614B6 (sk) Vakcína proti chrípke a spôsob jej prípravy
DE60224843T2 (de) Herstellung von viren, virusisolaten, und impfstoffen
DE19612966B4 (de) MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
EA014062B1 (ru) Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк
EP2216400A1 (de) Verfahren zur Herstellung eines aktiven Bestandteils eines Arznei- oder Diagnosemittels in MDCK-Zell-Suspensionskultur
CN104780936A (zh) 猪流感血球凝集素与神经氨酸酶变体
ES2778928T3 (es) Producción a gran escala de virus en cultivos celulares
JP5843615B2 (ja) 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製
CN102223895A (zh) 生产pH稳定的包膜病毒的方法
EP3234113B1 (en) A method for a large scale virus purification
CN102858961A (zh) 新方法
CN116966287B (zh) 一种用于流感病毒裂解疫苗的裂解方法
HK1010833B (en) Influenza vaccine
DE19655440B4 (de) Verfahren zur Herstellung eines Influenzaimpfstoffs
CN117603922A (zh) 一种流感病毒裂解液、流感病毒抗原及其制备方法与应用
MXPA98002766A (en) Vaccine against influe
DE202013005130U1 (de) Influenza Virus Reassortierung

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: ABBOTT BIOLOGICALS B.V., CP WEESP, NL

Effective date: 20120830

PC4A Assignment and transfer of rights

Owner name: BGP PRODUCTS B.V., HOOFDDORP, NL

Free format text: FORMER OWNER: ABBOTT BIOLOGICALS B.V., WEESP, NL

Effective date: 20160523

MK4A Patent expired

Expiry date: 20180406